Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with ...

Thanks to Joanna from Poland, I have no measurable leukemia. Getting college-age kids to join the bone-marrow donor registry ...

A single-center retrospective study found the approval and use of new agents to treat chronic graft-versus-host disease (GVHD ...

Clinical, biological and radiological evidence suggested a diagnosis of central nervous system graft-versus-host disease (CNS-GvHD). After intrathecal infusion of methylprednisolone, the clinical ...

A new study finds that eliminating radiation from conditioning regimens in patients with dyskeratosis congenita undergoing ...

Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of ...

SER-155 has received FDA Fast Track designation for reducing the risk of infection and GvHD in patients undergoing HSCT. The early development of the program was supported by Combating ...

GVHD is a common and often fatal complication that can follow a bone marrow transplant, which occurs when the donated cells mount an immune response against the transplant recipient’s tissues ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...